Alphabet subsidiary X, which was created to focus on “moon shot projects," has just unveiled research from its mental health project known as Amber, specifically with respect to its works to find biomarkers to map depression. The news, first spotted by CNBC, is an outline of the work the project has been doing.
“Our journey started by asking the question: What if we could make brain waves as...
Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway.
The first, a randomized controlled trial of 1,149 Australian adults with insomnia and depressive symptoms, suggested...
The use of cognitive-behavioral therapy interventions, such as Big Health’s Sleepio program, has been found to improve both sleep and mental health in individuals with insomnia and clinically significant depressive symptoms, according to new research published in the Journal of Sleep Research.
Sleepio is a digital sleep-improvement program that offers personalized treatment base on a user’s...
Ginger, the San Francisco-based behavioral health startup formerly known as Ginger.io, announced today a $50 million Series D funding round. Advance Venture Partners and Bessemer Venture Partners headed the raise, which also saw participation from Cigna Ventures, Kaiser Permanente Ventures and LinkedIn Executive Chairman Jeff Weiner.
With this, the company said it has raised more than $120...
The University of California, Los Angeles announced yesterday the launch of an Apple-backed study that will use the tech company's devices to measure how sleep, physical activity and heart rate relate to depression and anxiety.
The three-year effort launches this week. It will recruit 150 UCLA Health patients for its pilot phase, the university wrote in an announcement. Another 3,000 participants...
Swedish pharma company Orexo is jumping into the American digital-therapeutics game with the announcement of two new products, deprexis for treating depression symptoms and vorvida, a treatment for problematic alcohol use.
The new treatments are coming to the US market thanks to relaxed FDA regulations surrounding digital health products for psychiatric disorders, which was enacted as a result...
About the author: Stephanie Nieman is a principal at SJF Ventures based in Durham, N.C. SJF Ventures is a venture capital fund investing in high-growth, positive-impact companies across the U.S. and an active healthcare investor.
The current COVID-19 pandemic and resulting need for schools and universities to close, and for families to socially distance and practice remote learning, have only...
Fitbit and Belgium-based FibriCheck have extended their partnership to bring the latter’s atrial fibrillation detection app to four new countries in the EU: France, Germany, Italy and Spain. It was previously made available to Fitbit smartwatch users in the UK, Ireland, the Netherlands and Belgium back in September 2019.
“For more than a decade, Fitbit has helped millions of people around the...
When it comes to mental health apps, validation is a hot topic. But studying those apps can pose some hefty challenges. A recent meta analysis published online in the Journal of Affective Disorders found that studies of apps for depressive symptoms had around a 50% dropout rate when accounting for bias.
However, researchers discovered that the rate was lower when the apps included a human...
Flow Neuroscience is working with outpatient clinics in London’s Harley Street district in a partnership that will see its brain stimulation headset be offered to patients as an add-on treatment for depression.
The Swedish startup announced this morning that around 10 centres, including the Chelsea Psychology Clinic, would start offering the device in combination with traditional therapy and...
